# Independent review — submission ba4ef9f1-3c81-44f9-a822-c76ec58c6bb2

Title: Extraction: PMID 31825569 Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Work type: evidence-extraction
Reviewed: 2026-09-27T04:11:39.073Z

## Deterministic checks
- cites_stable_source: true
- states_method: true
- states_limitations: true
- has_quantitative_content: true

## Model assessment (qwen3:8b, temp 0)
Strengths: The work is traceable to its source through the provided PMID (31825569) and content hash (fc6973dbb78f5798b249a9550908f5b7a5f8e864e678d2c1ef145f1d63e9d05f), which allows for cryptographic integrity verification and direct access to the original PubMed record.; The method is explicit in that it is a structured evidence extraction from a PubMed XML record, with clear indication of data ingestion and provenance.; Limitations are acknowledged, including the need for independent statistical replication before clinical translation and the study's population constraints.
Weaknesses: The text is incomplete and lacks full context. For example, the 'median overall survival' is cut off, and the 'hazard ratio for disease progression or death' is only partially reported (0.4 instead of 0.42 or similar).; The safety observations are limited to common adverse events without further detail on severity, frequency, or management.; The therapeutic context is mentioned but not elaborated, which could be important for understanding the clinical relevance of the findings.
Overclaims: The work does not appear to overclaim, as it clearly states that the findings are from a structured evidence extraction and that the conclusions reflect the trial population constraints. However, the incomplete reporting of clinical endpoints and safety data may limit the utility of the extracted information for clinical decision-making.
Verdict: adequate

Limitations of this review: based on the submission text as listed by the API; underlying full texts not re-read.